Search
The London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge Quarter
Dr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies. It has already...
Apr 29
Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and...
Apr 25
AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient...
Apr 25
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a...
Apr 23
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by...
Apr 23
Allucent: Alex MacDonald, VP, Global Head of Model-Informed Drug Development at Allucent, discusses how his team supports biotech companies throughout the drug development journey
From the role of Clinical Pharmacology Modeling and Simulation to designing smarter early-phase studies and anticipating emerging trends,...
Apr 23
Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses
Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group...
Apr 22
Biotech CEO Sisterhood: Named CEO of Acadia Pharmaceuticals in September, Catherine Owen Adams describes taking the leap from a career in 'pharma' to running an independent, commercial stage biotech
Interviewed by Sisterhood editorial board member Julia Owens, Catherine Owen Adams shares her career journey, and discusses the perceived...
Apr 22
BioVenture VoiCes Episode 17: Norwest Venture Partners' Tiba Aynechi
Tiba Aynechi describes her career path, which has been spent entirely in the Bay Area since she earned her PhD from UCSF in the early...
Apr 21
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes...
Apr 17
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research...
Apr 16
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors...
Apr 16
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system...
Apr 15
Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target
CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at...
Apr 15
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to...
Apr 14
Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why
Dr. Schlessinger describes how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop...
Apr 10
Off-Target Effects Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector
One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs,...
Apr 10
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover
They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs....
Apr 9
Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year
CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic...
Apr 9
Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June
He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates,...
Apr 9
.png){kind=logo}
